ABSTRACT Background: The role of folate in skin carcinogenesis is unclear, with experimental data suggesting potentially protective but also deleterious effects. Objective: Our main objective was to investigate the prospective association between dietary folate intake and risks of skin cancer (overall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma (BCC). As an exploratory analysis, we also investigated the prospective association between erythrocyte folate concentration and skin cancer risk. Design: In this study, we included 5880 participants in the Suppl ementation en Vitamines et Min eraux Antioxydants (SU.VI.MAX) cohort (follow-up: 1994-2007) who completed at least six 24-h dietary records during the first 2 y of the study. Associations between sexspecific tertiles of dietary and erythrocyte folate and skin cancer risk were assessed by using multivariate Cox proportional hazards models. Results: After a median follow-up of 12.6 y, 144 incident skin cancers were diagnosed. Dietary folate intake was associated with increased risk of overall skin cancer [HR for tertile 3 compared with tertile 1 (HR T3vs.T1 ): 1.79; 95% CI: 1.07, 2.99; P-trend = 0.03], NMSC (HR T3vs.T1 : 1.85; 95% CI: 1.06, 3.23; P-trend = 0.03), and BCC (HR T3vs.T1 : 1.78; 0.98, 3.24; P-trend = 0.05). This association was observed in women (corresponding P-trend = 0.007, 0.009, and 0.009, respectively) but not in men (P-trend = 0.8, 0.8, and 0.9, respectively). P-interaction values between tertiles of dietary folate intake and sex were 0.04, 0.02, and 0.02 for overall skin cancer, NMSC, and BCC, respectively. Erythrocyte folate concentration was directly associated with increased risk of overall skin cancer (HR T3vs.T1 : 2.54; 95% CI: 0.95, 6.81; P-trend = 0.03), NMSC (HR T3vs.T1 : 3.49; 95% CI: 1.11, 11.0; P-trend = 0.01), and BCC (HR T3vs.T1 : 7.44; 95% CI: 1.57, 35.3; P-trend = 0.004) (men and women combined). Conclusions: This prospective study suggests an association between dietary folate intake and erythrocyte folate concentration and increased risk of overall skin cancer, NMSC, and BCC. Although several mechanistic hypotheses and 2 previous large prospective studies on BCC are in line with these results, epidemiologic literature is limited, and future research is needed to better elucidate the potential role of folate in the cause of skin cancers. The SU.VI.MAX trial was registered at clinicaltrials.gov as NCT00272428.
INTRODUCTION
The incidence of skin cancers has risen dramatically in Western countries over the past decades (1, 2) . In particular, in France, a 3-fold increase of skin cancer incidence was observed between 1980 and 2012 (2), probably because of both the aging of the population and the fashionable sun and artificial UV-exposure practices. Of skin cancers, melanoma, squamous cell carcinoma (SCC), 5 and basal cell carcinoma (BCC) are the most common forms. Nonmelanoma skin cancers (NMSCs), including SCC, BCC, and less-common forms, represent .90% of all skin cancers (2, 3) . Although BCC can be considered a slowly growing tumor that is often easily surgically curable, its treatment represents a high economic burden (3) . In addition, although advanced disease is rare, in some patients, BCC can progress to a point that local therapy becomes inappropriate and patients have a disfiguring disease with a quite-poor prognosis (4) . The main risk factor for skin cancers is UV exposure (either intermittent exposure with sunburns for BCC or chronic exposure for SCC) (1, 5) . However, other individual factors may also play an important role in the cause of these multifactorial diseases. To our knowledge, the role of folate (vitamin B-9) in skin carcinogenesis has not been previously elucidated. Folate is involved in the regeneration of methionine, the precursor of S-adenosyl-L-methionine, which is the methyl donor for DNA methylation. Thus, folate deficiency has been related to carcinogenesis in various tissues via the alteration of nucleic acid methylation and the disruption of DNA integrity and repair (6) . However, in contrast, experimental studies showed that folate was photoreactive and generated DNA modifications when irradiated with UVA (360 nm) in the presence of DNA under cell-free conditions (7) .
To our knowledge, only 2 previous epidemiologic studies investigated the prospective association between dietary folate intake and risk of BCC, and both studies showed a direct association (8, 9) . One prospective study showed no association between folate intake and SCC (10) . In 2013, Vollset et al. (11) published a metaanalysis of 13 randomized control trials on folic acid supplementation in which no association was detected with melanoma and NMSC. However, the number of cases was limited (126 melanomas and 169 NMSCs), and no information was specifically available for BCC. To our knowledge, since then, no prospective study has been published on the topic.
Our main objective was to investigate the prospective association between dietary folate intake and skin cancer (overall skin cancers including melanoma and NMSC, NMSC only, and BCC only). It has been shown that the erythrocyte folate concentration adequately reflects tissue stores after intake (12) . Thus, as an exploratory analysis, we also investigated the prospective association between erythrocyte folate concentration and skin cancer risk.
METHODS

Study population
The SU.VI.MAX (Suppl ementation en Vitamines et Min eraux Antioxydants) study was a population-based, double-blind, placebocontrolled randomized trial (clinicaltrials.gov; NCT00272428) initially designed to assess the effect of a daily antioxidant supplementation at nutritional doses on the incidence of cardiovascular disease and cancer (13) . All participants took either a single daily capsule of a combination of 120 mg ascorbic acid, 30 mg vitamin E, 6 mg b carotene, 100 mg Se, and 20 mg Zn or a placebo. A total of 13,017 subjects were enrolled in 1994-1995. The intervention lasted from 1994 to 2002, and the postintervention observational period was from 2003 to 2007. Thus, the total follow-up was defined as the intervention plus observational follow-up (i.e., from 1994 to 2007). Participants were advised against taking any self-prescribed supplements during the trial in regular written and oral instructions during follow-up visits. Subjects provided written informed consent, and the study was approved by the Ethics Committee for Studies with Human Subjects at the Paris-Cochin Hospital (CCPPRB nos. 706 and 2364) and the Commission Nationale de l'Informatique et des Libert es (nos. 334641 and 907094).
Dietary data collection
During the trial phase (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) , participants were invited to complete a dietary record every 2 mo in which they declared all foods and beverages consumed during periods of 24 h. These dietary records were randomly distributed between week and weekend days and over seasons to take into account the intraindividual variability. To be consistent with a prospective design, only dietary records from the first 2 y of follow-up were used in the current study for main analyses. Completion was made through the Minitel Telematic Network, which is a French telephone-based terminal equivalent to an Internet prototype. Portion sizes were assessed by using a validated picture booklet (14) , and amounts consumed from composite dishes were estimated by using French recipes validated by food and nutrition professionals. Mean daily energy, alcohol, folate, and other nutrient intakes were estimated by using a published French food-composition table (15). Dietary folate intake did not include folate intake from supplements. There is no systematic folic acid fortification of flour in France. For the few food items that were fortified with folic acid in the French market (mainly some breakfast cereals), mean nutritional values in the food-composition table took into account fortification. Thus, dietary folate intake was expressed in dietary folate equivalents (DFEs) (16) .
Erythrocyte folate analysis
At years 2 and 5, participants were invited to participate in a medical visit during which a fasting blood sample was drawn by venipuncture. Although recommended, these visits were not mandatory, and missing a visit was not a criterion for exclusion. Some subjects did not provide blood samples at year 2; thus, when available, their blood samples at year 5 were used in the analysis. Fasting blood was collected in EDTA-containing tubes, which were centrifuged within the hour after the blood sampling at room temperature for 10 min at 3000 3 g. The plasma fraction was transferred to cryotubes, which were kept at 2208C in visit centers for a maximum 7 d before shipment in dry ice to the coordinating center. At the center, samples were immediately stored at 2808C until laboratory measurements 6 mo later. For erythrocyte folate analysis, aliquots of whole-blood samples were diluted with 57 mmol ascorbic acid/L (1:11; volume:volume) and incubated for 1 h in a water bath at 378C for deconjugation of polyglutamyl folates by the action of plasma pteroylglutamate hydrolase activity. Folate concentrations were estimated with a microbiological assay by using Lactobacillus casei American Type Culture Collection 7469 (Lactobacillus rhamnosus; Institut Pasteur) with folic acid casei medium [Difco Laboratories (17) ]. The CV for each assay (intraassay and interassay) was ,7%. Erythrocyte folate values were calculated by using the packed cell volume measured by microcentrifugation (18) .
Data collection for covariates
At enrollment, self-administered questionnaires were filled-in by participants about sociodemographic characteristics, smoking status, medication use, family history of cancer, and phototype according to Fitzpatrick classification. Baseline physical activity was self-evaluated by asking participants if they currently practiced a regular physical activity and, if yes, if it was equivalent to #1 h walking/d. Anthropometric measurements (height and weight) were taken by study nurses and physicians during a baseline clinical examination. The dwelling latitude of the administrative center was retrieved for each French department of living. Participants completed a 14-item questionnaire on lifetime sun exposure and protection behaviors, which were specifically developed in the context of the SU.VI.MAX study, with 6 questions that investigated the awareness of risks related to sun exposure. A validated score of intensity of lifetime sun exposure was computed by using a principal component analysis for each participant (19) (20) (21) (22) .
Case ascertainment
Health events that occurred during follow-up were self-reported by participants. Medical data were gathered through participants, physicians, and hospitals and reviewed by an independent physician expert committee. Pathological reports were used to validate cases and to extract cancer characteristics. Cancers were classified by using the International Chronic Diseases Classification, 10th Revision, Clinical Modification (23). All first-incident primary skin cancers were considered cases in this study [i.e., melanoma and nonmelanoma (SCC and BCC) skin cancers].
Statistical analyses
From the 13,017 participants in the SU.VI.MAX study, 161 subjects were excluded because they reported a cancer diagnosis before the start of follow-up. We also excluded 3521 participants with missing lifetime sun exposure (a major potential confounding factor). Of remaining participants, 5880 subjects provided $6 valid 24-h dietary records within the first 2 y of follow-up and, thus, were included in the analyses. For all other covariates, ,5% of values were missing and were replaced by the mode.
Baseline characteristics of participants were compared across sex-specific tertiles of dietary folate intake by using t tests for quantitative variables and chi-square tests for qualitative variables. HRs and 95% CIs obtained from Cox proportional hazards models with age as the primary time variable were used to characterize the association between sex-specific tertiles of dietary folate intake and skin cancer risk (overall, NMSC, and BCC). Participants contributed person-time to the Cox models until the date of diagnosis of cancer, date of the last completed questionnaire, date of death, or September 2007, whichever occurred first. Participants who reported another cancer than the one studied during the study period were included and censored at the date of diagnosis. We confirmed that the assumptions of proportionality were satisfied through examination of the log-log (survival) compared with log-time plots.
Of participants who were eligible for the current study, an erythrocyte folate concentration was available for a subsample of 1760 subjects who were randomly selected from the SU.VI.MAX cohort. These laboratory analyses were initially performed with the aim to describe folate status and other blood variables in relation with dietary intake (24) . As an exploratory analysis, Cox models were also performed to investigate prospective associations between sex-specific tertiles of erythrocyte folate concentration and skin cancer risk. Participants contributed person-time to these Cox models from their date of blood sampling.
Multivariate models were adjusted for age (timescale in the Cox model), sex, intervention group of the initial SU.VI.MAX trial (antioxidant or placebo), number of dietary records (continuous), baseline BMI (continuous), physical activity (irregular, ,1 or $1 h walking/d, or the equivalent), smoking status (never, former, or current), educational level (university education or less), family history of cancer in first degree relatives (yes or no), score for lifetime sun exposure (quartiles), Fitzpatrick phototype (categories I-IV represented in this Caucasian population), latitude (quartiles), daily energy (continuous), and alcohol (continuous) intakes. Models related to erythrocyte folate were further adjusted for the month of blood draw.
Two-way interactions between dietary folate intake and sex and antioxidant supplementation were tested. Analyses were conducted overall and stratified by sex. Tests for linear trends were performed by using the ordinal score on tertiles of folate intake or erythrocyte folate concentration. As a sensitivity analysis, mean daily dietary folate intake was also calculated for each 2-y period between 1994 and 2002 (i.e., the nutritional assessment period in the SU.VI.MAX cohort) and was entered as a time-dependent variable in the Cox model (repeated-measurement analysis). All tests were 2-sided, and P , 0.05 was considered statistically significant. SAS version 9.3 software (SAS Institute) was used for analyses.
RESULTS
The median follow-up time was 12.6 y. A total of 5.2% of subjects were lost to follow-up. A total of 144 incident skin cancer cases were diagnosed (20 melanoma, 18 SCC, and 106 BCC). The mean 6 SD age at diagnosis was 57.9 6 7.0 y. The mean 6 SD number of 24-h dietary records was 10.8 6 2.3. Mean daily dietary folate intake was 313 mg DFE/d in included subjects with $6 dietary records and 304 mg DFE/d in excluded subjects with 1-5 dietary records (n = 1736). Although significant (P = 0.01), this difference represented ,3% of the mean intake. Mean (6SE) age-and energy-adjusted dietary folate intake was higher in women than in men (322 6 1.3 compared with 301 6 1.5 mg DFE/d, respectively; P , 0.0001), which was consistent with higher mean (6SE) fruit and vegetable intake (416 6 2.8 compared with 351 6 3.4) g/d, respectively; P , 0.0001). The 95th percentile of folate intake was 473 mg/d.
Characteristics of participants are described in Table 1 . Subjects with higher dietary folate intake tended to be slightly older, more physically active, and nonsmokers and have a higher educational level and higher energy intake. ; P-trend = 0.007) for overall skin cancer, 3.12 (95% CI: 1.34, 7.26; P-trend = 0.009) for NMSC, and 3.28 (1.34, 8.00; P-trend = 0.009) for BCC] but was NS in men (P-trend = 0.8, P-trend = 0.8, and P-trend = 0.9, respectively) despite a similar statistical power in both sex strata (P-interaction between tertiles of dietary folate intake and sex = 0.04, 0.02 ,and 0.02 for overall skin cancer, NMSC, and BCC, respectively). Results for women were unchanged when postmenopausal women only were focused on [HR T3vs.T1 : 2.55 (95% CI: 1.11, 5.85; P-trend = 0.02) for overall skin cancer, 3.17 (95% CI: 1.27, 7.90; P-trend = 0.009) for NMSC, and 3.38 (95% CI: 1.28, 8.98; P-trend = 0.008) for BCC; data not tabulated). No interaction was detected between dietary folate intake and the antioxidant supplementation group of the SU.VI.MAX trial (P-interaction = 0.7 for overall skin cancer, P-interaction = 0.6 for NMSC, and P-interaction = 0.6 for BCC). Similar results were obtained when cancer cases diagnosed during the first 2 y of follow-up were excluded (data not shown).
Sensitivity analyses that considered dietary folate intake as a time-dependent variable provided similar results; for all skin cancers, HR T3vs.T1 was 0.79 (95% CI: 0.40, 1.58; P-trend = 0.5) in men and 2.15 (95% CI: 1.09, 4.24; P-trend = 0.02) in women; for NMSC, HR T3vs.T1 was 0.81 (95% CI: 0.39, 1.70; P-trend = 0.6) in men and 2.22 (95% CI: 1.04, 4.72; P-trend = 0.03) in women; and for BCC, HR T3vs.T1 was 0.83 (95% CI: 0.37, 1.87; P-trend = 0.6) in men and 2.48 (95% CI: 1.10, 5.60; P-trend = 0.03) in women.
The proportion of blood folate checked at the earlier time point (year 2) was similar in cancer subjects and noncancer subjects (56% and 60%, respectively; P = 0.7). The exploratory analysis of the association between erythrocyte folate concentration and skin cancer risk is shown in Table 3 . The folate concentration in red blood cells was directly associated with increased risk of overall skin cancer (HR T3vs.T1 : 2.54; 95% CI: 0.95, 6.81; P-trend = 0.03), NMSC (HR T3vs.T1 : 3.49; 95% CI: 1.11, 11.0; P-trend = 0.01), and BCC (HR T3vs.T1 : 7.44; 95% CI: 1.57, 35.3; P-trend = 0.004).
DISCUSSION
In this prospective study, dietary folate intake was associated with increased risk of overall skin cancer, NMSC, and BCC. Despite a small subsample size, the exploratory analysis consistently showed an association between a higher erythrocyte folate concentration and increased risk of overall skin cancer, NMSC, and BCC. Epidemiologic literature regarding the association between folate intake and skin cancer risk is limited. Consistent with our findings, the only 2 prospective studies, to our knowledge, on folate intake and BCC risk showed a direct association (8, 9) . The first study was a prospective cohort study (Health Professionals Followup Study) in which 3190 men were diagnosed with BCC and increased risk of BCC associated with folate intake was observed (HR for quartile 5 compared with quartile 1: 1.19; 95% CI: 1.01, 1.40) (8) . The second study included 5392 BCC cases in women and provided similar results with a HR for quartile 5 compared with quartile 1 of 1.20 (95% CI: 1.10, 1.31) (9). In contrast, one prospective study showed no association between dietary folate intake and SCC (10) , and a recent meta-analysis of 13 randomized control trials on folic acid supplementation detected no association with NMSCs (11). In the same meta-analysis, Vollset et al. (11) did not observe any association with melanoma skin cancers. However, the number of cases was limited (126 melanomas and 189 NMSCs), and no information was specifically available for BCC in this meta-analysis (11) . The same year, another meta-analysis was published (25) that suggested an inverse association between folic acid supplementation and melanoma risk, but this study only included 3 trials. To our knowledge, since then, no prospective study was published on the topic.
In this study, the direct association between dietary folate intake and risk of overall skin cancer, NMSC, and BCC was more specifically observed in women. In contrast, this association was significant in both men (8) and women (9) in the 2 previous prospective studies that investigated this relation for BCC. One explanation of our findings could be that women had higher ageand energy-adjusted dietary folate intake than did men. Mean 6 SE daily folate intake was 322 6 1.3 mg DFE/d in women [which was higher than nutritional recommendations for French adult women (i.e., 300 mg/d)] and 301 6 1.5 mg DFE/d in men [which was below nutritional recommendations for men (i.e., 330 mg/d)] (26). Differences in the causes of skin cancers between men and women, such as a potential modulation by hormonal factors, could also have contributed to explain this results, but additional research is needed to elucidate this point.
In the SU.VI.MAX trial, antioxidant supplementation was associated with increased skin cancer risk in women but not in men (27) . Thus, the possibility that antioxidant supplementation might have increased skin cancer risk and high folate intake might have potentiated this effect could not be ruled out. However, the interaction between folate intake and the group of intervention was NS and, thus, did not support this hypothesis.
Mean folate intake in the third tertile was above French recommendations (26) but was close to US recommendations [400 mg DFE (28)]. Consistently in the 2 US cohorts in whom folate intake was associated with increased BCC risk, median intakes (food and supplements) in the third quintile, for which the increased risk was already observed, did not reach pharmacologic doses either [345 mg DFE/d (9) and 388 mg DFE/d (8)].
As is usually the case in observational studies, higher intakes of nutrients (such as folate) were observed in subjects with higher energy intakes because as they ingest higher quantities of food, they have higher absolute intakes for most micronutrients and macronutrients. However, energy is not an established risk factor for skin cancers (29) , and all of our models were adjusted for energy intake. Thus, major confounding by energy intake was unlikely.
Although some mechanistic data suggest a protective role of folate in skin carcinogenesis (6, 30) , other data support a positive association in line with our findings. One possible explanation is that rapidly proliferating cells in tumor tissues require high concentrations of folate to continue DNA synthesis and cellular replication (31) . There has been some evidence from experimental studies that anti-folate drugs such as methotrexate might induce apoptosis of melanoma (32) (33) (34) and SCC cell lines (35) . Besides, in a recent study on human cell lines, phototoxic and photogenotoxic effects of folic acid were shown through the observation of the action of irradiated folic acid on cell-free DNA (7). Moreover, it has been observed that perigestational dietary folic acid deficiency protected against medulloblastoma formation in a mouse model of nevoid BCC syndrome (36) . More generally, growing evidence in several cancers such as colorectal cancer or prostate cancer supports a dual role of folate in carcinogenesis (37) (38) (39) . Indeed, although high folate intake may be protective against the initiation of carcinogenesis through increased genetic stability, it may also be detrimental by enhancing cell proliferation, especially if cells are already neoplastic, as shown in animal studies in which folate depletion inhibited tumor growth (37) (38) (39) .
Studies related to genetic polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene also provided interesting insights that are consistent with the results of our exploratory analysis on erythrocyte folate. MTHFR plays a central role in the folate pathway by catalyzing the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the major circulating form of folate. The 2 main polymorphisms of MTHFR C677T and A1298C lead to a decrease in MTHFR activity and plasma folate concentrations (40) (41) (42) , but they are also associated with a significant increase in erythrocyte folate concentration (41) . Both MTHFR polymorphisms have been associated with increased risk of SCC (43) (44) (45) , BCC (46, 47) , and NMSC (48) in several epidemiologic studies. Unfortunately, data regarding the MTHFR C677T polymorphism was only available for a very small number of subjects in this cohort [n = 291 (49)] and, thus, could not be used for the etiologic analyses.
Strengths of this study included its prospective design and a long follow-up. Moreover, dietary data were accurately assessed by using repeated 24-h dietary records, which accounted for intraindividual day-to-day and seasonal variability. Some limitations should be acknowledged. The main weakness of this study was the limited statistical power. Although the number of cases was sufficient to perform analyses on BCC, the number of cases for other skin cancers was limited. Although results seemed to be consistent across all skin cancers in this study, it could not be ruled out that observed findings could have been driven by those of BCCs. Besides, the statistical power was very limited regarding erythrocyte folate concentration, and thus, no stratification by sex was possible. This analysis should only be considered as an exploratory investigation. However, the results of this study were consistent with those observed for dietary folate intake and were in line with mechanistic and genetic data. The limited statistical power may have limited our ability to detect some associations but was unlikely to explain the observed relations that were significant despite this potential power limitation. Next, supplement use during the postintervention phase (2002) (2003) (2004) (2005) (2006) (2007) was not recorded. However, overall supplement use (all types) only concerned 17% of the cohort at the end of follow-up in 2007, and analyses in which these subjects were excluded revealed similar trends. Besides, except in pregnant women, folic acid supplement use is low in France [,5% (50) ]. Last, although very low folate intake may also convey increased skin cancer risk, this relation could not be investigated in our study. Indeed, participants were volunteers involved in a nutrition study and, thus, had more-healthy dietary behaviors and higher dietary folate intakes than in the general population. Thus, caution is needed when extrapolating these results to the entire French adult population.
In conclusion, this prospective study suggests an association between dietary folate intake, erythrocyte folate concentration (exploratory analysis), and increased risk of overall skin cancer, NMSC, and BCC. Although several mechanistic hypotheses and 2 previous large prospective studies on BCC are in line with these results, epidemiologic literature is limited and future research is needed to better elucidate the potential role of folate in the cause of the different skin cancer types. The confirmation of these findings by future large-scale studies is necessary before deriving any conclusion or recommendation for the general population.
